{"name":"Peplin","slug":"peplin","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Dermatology","slug":"dermatology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Lesion count","genericName":"Lesion count","slug":"lesion-count","indication":"Tracking and monitoring lesions in various dermatological conditions","status":"phase_2"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"PEP005 (ingenol mebutate) Gel","genericName":"PEP005 (ingenol mebutate) Gel","slug":"pep005-ingenol-mebutate-gel","indication":"Actinic keratosis (field treatment on face or scalp)","status":"phase_3"}]}],"pipeline":[{"name":"Lesion count","genericName":"Lesion count","slug":"lesion-count","phase":"phase_2","mechanism":"Lesion count drug works by counting and tracking lesions in the body.","indications":["Tracking and monitoring lesions in various dermatological conditions"],"catalyst":""},{"name":"PEP005 (ingenol mebutate) Gel","genericName":"PEP005 (ingenol mebutate) Gel","slug":"pep005-ingenol-mebutate-gel","phase":"phase_3","mechanism":"Ingenol mebutate activates protein kinase C (PKC) to induce rapid necrosis of actinic keratosis cells and trigger immune-mediated clearance of remaining lesions.","indications":["Actinic keratosis (field treatment on face or scalp)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTFBkSTZ2X1hUY0QtVkVNN3RsY2RwWnVMT0NhVkhybmoweXUyZWREbWxQQWNDdktiUzRCSk5lREUzZzJNWktfM3hfM0kyNnRicFJaaFk0?oc=5","date":"2022-03-07","type":"pipeline","source":"BioSpace","summary":"Three More Biopharma Companies Shuffle Executive Deck - BioSpace","headline":"Three More Biopharma Companies Shuffle Executive Deck","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxPcEZNYW1XeHdLS0lVZFF6bHdyWWItQV8zS2hjTmN2WkhuZTQwYkRteDVBOUVPYUNfaGxPQ1BBY2NWLWZuTUdhQXFRZnBKYnlWRF9pblVudHVwLXVBckVKYmpLNE1OOXVHWEJocTBBeTJEbUFJdWJSZmR2eVJYa1dJVkxMWnlmOGJIbHdIZVdGazlkcGNyWE11T2tJN1J5OElpcTZ4TXpMc1FvNzhoSUlxaTB4ODl4dG1wMGZlLQ?oc=5","date":"2019-07-21","type":"pipeline","source":"Crain's Detroit","summary":"Sooch raises $5 million for new venture, ophthalmology pharma company Ocuphire - Crain's Detroit","headline":"Sooch raises $5 million for new venture, ophthalmology pharma company Ocuphire - Crain's Detroit","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxORnpCbWlhRDY2allvSk9ZR3UwYmxfRXFwWmZHYUxieFEyUEswd3gza3FMSFFsOXVjRWVGMExHUDZmTEJ2dzhTU1hSSl9rWGh2Rm1TWEZMUjc5TGt6OHkzMlR4NkRZM3NUSkczT1hsYXVkY2o3VWMzMXdVR1V2b2dxOQ?oc=5","date":"2019-07-17","type":"pipeline","source":"nhmrc.gov.au","summary":"Picato® gel - nhmrc.gov.au","headline":"Picato® gel","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxOTWYyYzNESWtnVWlvTU5HMmdVakh0N3pLQXN4MzhJWThWRFpaT21oYi1HcnVtQlFkaVlubC1MbjlWZmdMSXZEc1ZfYjdLZVIxNDh6Zjhld05wTUtCR1FFTzFYYTNfQ2NIWTVZMjBib0JLVzNISVpCcUNMX20yaE4xYUdLaHRwbzhlc3NB?oc=5","date":"2015-01-16","type":"pipeline","source":"FinSMEs","summary":"New Enterprise Associates Announces Promotions - FinSMEs","headline":"New Enterprise Associates Announces Promotions","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTFB2X0NyQlc5VW5yVkloeUVibnZYVmhMbXhGSlNsSFF4RlRFMDBuWEFnbE5aM29IekZKNjdwdExfcTRSMTVGaWo2c3NESVNqME4yeGkzTGloQkFMUEJjclFRTXJsWjd2dDlTbVZqUHZhOWJQRkdETWREb1lSeDdrb0E?oc=5","date":"2009-09-03","type":"pipeline","source":"Genetic Engineering and Biotechnology News","summary":"LEO Pharma to Take Over Peplin for $287.5M - Genetic Engineering and Biotechnology News","headline":"LEO Pharma to Take Over Peplin for $287.5M","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":1,"phase_3":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}